Results 171 to 180 of about 2,249 (191)

Immunoglobulin interface redesigning to enhance lebrikizumab mediated immunomodulation of IL-13 hyper-response

Journal of Biomolecular Structure and Dynamics, 2021
Rajan Kumar Pandey, Rupal Ojha, Veeranarayanan Surya Aathmanathan   +2 more
exaly  

Lebrikizumab-lbkz

American Journal of Health-System Pharmacy
openaire   +2 more sources

Lebrikizumab safe in adolescents and adults with atopic dermatitis

Reactions Weekly, 2023
openaire   +1 more source

Intriguing findings on lebrikizumab for treating moderate-to-severe atopic dermatitis

British Journal of Dermatology, 2023
openaire   +2 more sources

Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids

Journal of Allergy and Clinical Immunology, 2013
Phillip Korenblat, Joseph R Arron, Yanan Zheng   +2 more
exaly  

Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis

New England Journal of Medicine, 2023
exaly  

Efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma not receiving inhaled corticosteroids

Respiratory Medicine, 2018
Phillip Korenblat, I V Leshchenko, Cecile T J Holweg   +2 more
exaly  

The Rebirth of Lebrikizumab for Airway Disease

The Journal of Allergy and Clinical Immunology: In Practice
openaire   +2 more sources

Results from 1 year of treatment with lebrikizumab for atopic dermatitis

British Journal of Dermatology, 2023
openaire   +2 more sources

Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthma

Pulmonary Pharmacology and Therapeutics, 2017
Yanan Zheng, Nathanael L Dirks, Shweta Vadhavkar   +2 more
exaly